Tyber Medical gets USD225,000 NSF competitive grant
13 March 2019 -

Orthopaedic device company Tyber Medical, LLC reported on Tuesday the receipt of the National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant, valued at USD225,000, to conduct research and development (R&D) work aimed at reducing the incidence of orthopaedic surgical site infections (SSI).

The company said it is aggressively exploring the antibacterial characteristics of its unique nanotextured implant surface, which is known under the trade-named BioTy, to address the severe clinical and economical effects of orthopaedic device-related infections.

Through the second-generation BioTy surface technology, the company controls the bacterial colonisation on implant surfaces using topography alone, without incorporating antimicrobial agents or pharmaceuticals to which bacteria could form resistances.

Following the Phase I SBIR/STTR grant of up to USD225,000, the company is eligible to apply for a Phase II grant of up to USD750,000. Small businesses with Phase II grants are eligible to receive up to USD500,000 in additional matching funds with qualifying third-party investment or sales.